Tumour-microenvironmental interactions: Paths to progression and targets for treatment

Seminars in Cancer Biology

Volumn 20, Issue 3, 2010, Pages 128-138

  Box, Carol ^a   Rogers, Susanne J ^a   Mendiola, Marta ^a   Eccles, Suzanne A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer progression; Cell adhesion molecules; Cell signalling; Drug resistance; Tumour microenvironment

Indexed keywords

2 [5 CHLORO 2 (2 METHOXY 4 MORPHOLINOANILINO) 4 PYRIMIDINYLAMINO] N METHYLBENZAMIDE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BB 10901; CATUMAXOMAB; CETUXIMAB; CILENGITIDE; CNTO 95; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EXHERIN; FLUOROURACIL; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; GEFITINIB; GEMCITABINE; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; INTEGRIN; MONOCLONAL ANTIBODY LM 609; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; PACLITAXEL; PF 03732010; PF 04554878; PF 04605412; PF 562271; PND 1186; REMOVAB; SEMAPHORIN 3F; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VOLOCIXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; BRAIN TUMOR; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CELL HYPOXIA; CELL INTERACTION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; METASTASIS; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PERITONEUM CANCER; PROSTATE CANCER; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UTERINE TUBE TUMOR;

ANIMALS; CELL COMMUNICATION; DISEASE PROGRESSION; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT;

EID: 77956619068     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2010.06.004     Document Type: Review

References (161)

1. Durand R.E., Olive P.L. Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. Methods Cell Biol 2001, 64:211-233.
2. Li C.L., Tian T., Nan K.J., Zhao N., Guo Y.H., Cui J., et al. Survival advantages of multicellular spheroids vs. monolayers of HepG2 cells in vitro. Oncol Rep 2008, 20:1465-1471.
3. Ivascu A., Kubbies M. Diversity of cell-mediated adhesions in breast cancer spheroids. Int J Oncol 2007, 31:1403-1413.
4. Friedrich J., Seidel C., Ebner R., Kunz-Schughart L.A. Spheroid-based drug screen: considerations and practical approach. Nat Protoc 2009, 4:309-324.
5. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol. 2010; 148: 3-15.
6. L'Esperance S., Bachvarova M., Tetu B., Mes-Masson A.M., Bachvarov D. Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics 2008, 9:99.
7. Weaver V.M., Lelievre S., Lakins J.N., Chrenek M.A., Jones J.C., Giancotti F., et al. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002, 2:205-216.
8. Kantak S.S., Kramer R.H. E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. J Biol Chem 1998, 273:16953-16961.
9. Hauptmann S., Denkert C., Lohrke H., Tietze L., Ott S., Klosterhalfen B., et al. Integrin expression on colorectal tumor cells growing as monolayers, as multicellular tumor spheroids, or in nude mice. Int J Cancer 1995, 61:819-825.
10. Grantab R., Sivananthan S., Tannock I.F. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res 2006, 66:1033-1039.
11. St Croix B., Man S., Kerbel R.S. Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Lett 1998, 131:35-44.
12. Green S.K., Francia G., Isidoro C., Kerbel R.S. Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther 2004, 3:149-159.
13. Zheng C., Zhou Q., Wu F., Peng Q., Tang A., Liang H., et al. Semaphorin3F down-regulates the expression of integrin alpha(v)beta3 and sensitizes multicellular tumor spheroids to chemotherapy via the neuropilin-2 receptor in vitro. Chemotherapy 2009, 55:344-352.
14. Chen Y.Y., Wang Z.X., Chang P.A., Li J.J., Pan F., Yang L., et al. Knockdown of focal adhesion kinase reverses colon carcinoma multicellular resistance. Cancer Sci 2009, 100:1708-1713.
15. Tanjoni I, Walsh C, Uryu S, Tomar A, Nam JO, Mielgo A, et al. PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biol Ther 2010; 9:764-77.
16. Kang H.G., Jenabi J.M., Zhang J., Keshelava N., Shimada H., May W.A., et al. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res 2007, 67:3094-3105.
17. Mougel L., Tarpin M., Albert P., Le Naour R., Devy J., Kaplan H., et al. Three-dimensional culture and multidrug resistance: effects on immune reactivity of MCF-7 cells by monocytes. Anticancer Res 2004, 24:935-941.
18. Westhoff M.A., Fulda S. Adhesion-mediated apoptosis resistance in cancer. Drug Resist Update 2009, 12:127-136.
19. Meads M.B., Gatenby R.A., Dalton W.S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009, 9:665-674.
20. Bansal N., Banerjee D. Tumor initiating cells. Curr Pharm Biotechnol 2009, 10:192-196.
21. Bjerkvig R., Johansson M., Miletic H., Niclou S.P. Cancer stem cells and angiogenesis. Semin Cancer Biol 2009, 19:279-284.
22. Behbod F., Rosen J.M. Will cancer stem cells provide new therapeutic targets?. Carcinogenesis 2005, 26:703-711.
23. Blagosklonny M.V. Target for cancer therapy: proliferating cells or stem cells. Leukemia 2006, 20:385-391.
24. Wicha M.S., Liu S., Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res 2006, 66:1883-1890. discussion 1895-6.
25. Hirschmann-Jax C., Foster A.E., Wulf G.G., Nuchtern J.G., Jax T.W., Gobel U., et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004, 101:14228-14233.
26. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
27. Brabletz T., Jung A., Spaderna S., Hlubek F., Kirchner T. Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer 2005, 5:744-749.
28. Athale C., Mansury Y., Deisboeck T.S. Simulating the impact of a molecular 'decision-process' on cellular phenotype and multicellular patterns in brain tumors. J Theor Biol 2005, 233:469-481.
29. Condeelis J., Singer R.H., Segall J.E. The great escape: when cancer cells hijack the genes for chemotaxis and motility. Annu Rev Cell Dev Biol 2005, 21:695-718.
30. Walia V, Elble RC. Enrichment for breast cancer cells with stem/progenitor properties by differential adhesion. Stem Cells Dev 2010; ahead of print. doi:10.1089/scd.2009.0430.
31. Sakariassen P.O., Prestegarden L., Wang J., Skaftnesmo K.O., Mahesparan R., Molthoff C., et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A 2006, 103:16466-16471.
32. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
33. Hazlehurst L.A., Landowski T.H., Dalton W.S. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 2003, 22:7396-7402.
34. Zhi L, Wang M, Rao Q, Yu F, Mi Y, Wang J. Enrichment of N-cadherin and Tie2-bearing CD34(+)/CD38(-)/CD123(+) leukemic stem cells by chemotherapy-resistance. Cancer Lett. 2010; ahead of print. doi:101016/j.canlet.2010.03.021.
35. Wang L., Fortney J.E., Gibson L.F. Stromal cell protection of B-lineage acute lymphoblastic leukemic cells during chemotherapy requires active Akt. Leuk Res 2004, 28:733-742.
36. Matsunaga T., Fukai F., Miura S., Nakane Y., Owaki T., Kodama H., et al. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia 2008, 22:353-360.
37. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29:625-34.
38. Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide 2008, 19:205-216.
39. Kubota Y., Takubo K., Suda T. Bone marrow long label-retaining cells reside in the sinusoidal hypoxic niche. Biochem Biophys Res Commun 2008, 366:335-339.
40. Parmar K., Mauch P., Vergilio J.A., Sackstein R., Down J.D. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 2007, 104:5431-5436.
41. Das B., Tsuchida R., Malkin D., Koren G., Baruchel S., Yeger H. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 2008, 26:1818-1830.
42. Bleau A.M., Hambardzumyan D., Ozawa T., Fomchenko E.I., Huse J.T., Brennan C.W., et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4:226-235.
43. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010; 102:789-95.
44. Soeda A., Park M., Lee D., Mintz A., Androutsellis-Theotokis A., McKay R.D., et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009, 28:3949-3959.
45. Peinado H., Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer 2007, 7:415-428.
46. Schietke R, Warnecke C, Wacker I, Schodel J, Mole DR, Campean V, et al. The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1. J Biol Chem 2010; 285:6658-69.
47. Peinado H., Moreno-Bueno G., Hardisson D., Perez-Gomez E., Santos V., Mendiola M., et al. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. Cancer Res 2008, 68:4541-4550.
48. Zhou B.P., Deng J., Xia W., Xu J., Li Y.M., Gunduz M., et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004, 6:931-940.
49. Yoon S.O., Shin S., Mercurio A.M. Hypoxia stimulates carcinoma invasion by stabilizing microtubules and promoting the Rab11 trafficking of the alpha6beta4 integrin. Cancer Res 2005, 65:2761-2769.
50. Irigoyen M., Anso E., Martinez E., Garayoa M., Martinez-Irujo J.J., Rouzaut A. Hypoxia alters the adhesive properties of lymphatic endothelial cells. A transcriptional and functional study. Biochim Biophys Acta 2007, 1773:880-890.
51. Hersey P, Sosman J, O'Day S, Richards J, Bedikian A, Gonzalez R, et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer 2010; 116:1526-34.
52. Ruegg C, Alghisi GC. Vascular integrins: therapeutic and imaging targets of tumor angiogenesis. Recent Results Cancer Res 2010; 180:83-101.
53. Francavilla C., Maddaluno L., Cavallaro U. The functional role of cell adhesion molecules in tumor angiogenesis. Semin Cancer Biol 2009, 19:298-309.
54. Rak J., Mitsuhashi Y., Sheehan C., Krestow J.K., Florenes V.A., Filmus J., et al. Collateral expression of proangiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikis. Neoplasia 1999, 1:23-30.
55. Xiong Y.Q., Sun H.C., Zhang W., Zhu X.D., Zhuang P.Y., Zhang J.B., et al. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 2009, 15:4838-4846.
56. Bewick M.A., Lafrenie R.M. Adhesion dependent signalling in the tumour microenvironment: the future of drug targetting. Curr Pharm Des 2006, 12:2833-2848.
57. Thompson E.W., Newgreen D.F., Tarin D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition?. Cancer Res 2005, 65:5991-5995. discussion 5995.
58. Mercurio A.M., Rabinovitz I., Shaw L.M. The alpha 6 beta 4 integrin and epithelial cell migration. Curr Opin Cell Biol 2001, 13:541-545.
59. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005, 17:548-558.
60. Christiansen J.J., Rajasekaran A.K. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006, 66:8319-8326.
61. Fraley S.I., Feng Y., Krishnamurthy R., Kim D.H., Celedon A., Longmore G.D., et al. A distinctive role for focal adhesion proteins in three-dimensional cell motility. Nat Cell Biol. 2010, 12:598-604.
62. Hazan R.B., Qiao R., Keren R., Badano I., Suyama K. Cadherin switch in tumor progression. Ann N Y Acad Sci 2004, 1014:155-163.
63. Derycke L.D., Bracke M.E. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol 2004, 48:463-476.
64. Voulgari A., Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009, 1796:75-90.
65. Chiodoni C., Colombo M.P., Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev 2010, 29:295-307.
66. Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol 2010; 11: 288-300.
67. Nievers M.G., Schaapveld R.Q., Sonnenberg A. Biology and function of hemidesmosomes. Matrix Biol 1999, 18:5-17.
68. Grossman H.B., Lee C., Bromberg J., Liebert M. Expression of the alpha6beta4 integrin provides prognostic information in bladder cancer. Oncol Rep 2000, 7:13-16.
69. Tagliabue E., Ghirelli C., Squicciarini P., Aiello P., Colnaghi M.I., Menard S. Prognostic value of alpha 6 beta 4 integrin expression in breast carcinomas is affected by laminin production from tumor cells. Clin Cancer Res 1998, 4:407-410.
70. Fujita Y., Kitagawa M., Nakamura S., Azuma K., Ishii G., Higashi M., et al. CD44 signaling through focal adhesion kinase and its anti-apoptotic effect. FEBS Lett 2002, 528:101-108.
71. Avizienyte E., Wyke A.W., Jones R.J., McLean G.W., Westhoff M.A., Brunton V.G., et al. Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol 2002, 4:632-638.
72. Novak A., Hsu S.C., Leung-Hagesteijn C., Radeva G., Papkoff J., Montesano R., et al. Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc Natl Acad Sci U S A 1998, 95:4374-4379.
73. Tan C., Costello P., Sanghera J., Dominguez D., Baulida J., de Herreros A.G., et al. Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC-/- human colon carcinoma cells. Oncogene 2001, 20:133-140.
74. Makrilia N., Kollias A., Manolopoulos L., Syrigos K. Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest 2009, 27:1023-1037.
75. Eccles S.A. Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention. Int J Dev Biol 2004, 48:583-598.
76. Rolli M., Fransvea E., Pilch J., Saven A., Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:9482-9487.
77. Brooks P.C., Stromblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996, 85:683-693.
78. Eccles S.A., Paon L. Breast cancer metastasis: when, where, how?. Lancet 2005, 365:1006-1007.
79. Eccles S.A., Welch D.R. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007, 369:1742-1757.
80. Klemke M., Weschenfelder T., Konstandin M.H., Samstag Y. High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. J Cell Physiol 2007, 212:368-374.
81. Nguyen D.X., Bos P.D., Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009, 9:274-284.
82. Iiizumi M., Mohinta S., Bandyopadhyay S., Watabe K. Tumor-endothelial cell interactions: therapeutic potential. Microvasc Res 2007, 74:114-120.
83. Orr F.W., Wang H.H., Lafrenie R.M., Scherbarth S., Nance D.M. Interactions between cancer cells and the endothelium in metastasis. J Pathol 2000, 190:310-329.
84. Bandyopadhyay S., Zhan R., Chaudhuri A., Watabe M., Pai S.K., Hirota S., et al. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat Med 2006, 12:933-938.
85. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
86. Denhardt D.T., Noda M., O'Regan A.W., Pavlin D., Berman J.S. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001, 107:1055-1061.
87. Gehlsen K.R., Davis G.E., Sriramarao P. Integrin expression in human melanoma cells with differing invasive and metastatic properties. Clin Exp Metastasis 1992, 10:111-120.
88. Takayama N., Arima S., Haraoka S., Kotho T., Futami K., Iwashita A. Relationship between the expression of adhesion molecules in primary esophageal squamous cell carcinoma and metastatic lymph nodes. Anticancer Res 2003, 23:4435-4442.
89. Huanwen W., Zhiyong L., Xiaohua S., Xinyu R., Kai W., Tonghua L. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer 2009, 8:125.
90. Aoudjit F., Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001, 20:4995-5004.
91. Schmidt W.M., Kalipciyan M., Dornstauder E., Rizovski B., Steger G.G., Sedivy R., et al. Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int J Cancer 2004, 112:200-212.
92. Song J., Shih Ie M., Chan D.W., Zhang Z. Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. Neoplasia 2009, 11:605-614. 1 p. following 614.
93. Tajima K, Ohashi R, Sekido Y, Hida T, Nara T, Hashimoto M, et al. Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene 2010; 29:1941-51.
94. Lee J.L., Wang M.J., Sudhir P.R., Chen G.D., Chi C.W., Chen J.Y. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 2007, 67:2089-2097.
95. Noda T., Nagano H., Takemasa I., Yoshioka S., Murakami M., Wada H., et al. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 2009, 100:1647-1658.
96. Kraus A.C., Ferber I., Bachmann S.O., Specht H., Wimmel A., Gross M.W., et al. In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 2002, 21:8683-8695.
97. Tsurutani J., West K.A., Sayyah J., Gills J.J., Dennis P.A. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 2005, 65:8423-8432.
98. Dong Y, Tan OL, Loessner D, Stephens C, Walpole C, Boyle GM, et al. Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Cancer Res 2010; 70:2624-33.
99. Cordes N., Blaese M.A., Meineke V., Van Beuningen D. Ionizing radiation induces up-regulation of functional beta1-integrin in human lung tumour cell lines in vitro. Int J Radiat Biol 2002, 78:347-357.
100. Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A 2010; 107:8363-8.
101. Hehlgans S., Lange I., Eke I., Cordes N. 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226. Radiother Oncol 2009, 92:371-378.
102. Al Moustafa A.E., Yen L., Benlimame N., Alaoui-Jamali M.A. Regulation of E-cadherin/catenin complex patterns by epidermal growth factor receptor modulation in human lung cancer cells. Lung Cancer 2002, 37:49-56.
103. Pece S., Chiariello M., Murga C., Gutkind J.S. Activation of the protein kinase Akt/PKB by the formation of E-cadherin-mediated cell-cell junctions. Evidence for the association of phosphatidylinositol 3-kinase with the E-cadherin adhesion complex. J Biol Chem 1999, 274:19347-19351.
104. Wang F., Sloss C., Zhang X., Lee S.W., Cusack J.C. Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells. Cancer Res 2007, 67:8486-8493.
105. Huang D.H., Su L., Peng X.H., Zhang H., Khuri F.R., Shin D.M., et al. Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells. Nanotechnology 2009, 20:225102.
106. Engelman J.A., Janne P.A. Factors predicting response to EGFR tyrosine kinase inhibitors. Semin Respir Crit Care Med 2005, 26:314-322.
107. Engelman J.A., Janne P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008, 14:2895-2899.
108. Coldren C.D., Helfrich B.A., Witta S.E., Sugita M., Lapadat R., Zeng C., et al. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 2006, 4:521-528.
109. Frederick B.A., Helfrich B.A., Coldren C.D., Zheng D., Chan D., Bunn P.A., et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 2007, 6:1683-1691.
110. Yauch R.L., Januario T., Eberhard D.A., Cavet G., Zhu W., Fu L., et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005, 11:8686-8698.
111. Fujimoto N., Wislez M., Zhang J., Iwanaga K., Dackor J., Hanna A.E., et al. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 2005, 65:11478-11485.
112. Witta S.E., Gemmill R.M., Hirsch F.R., Coldren C.D., Hedman K., Ravdel L., et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006, 66:944-950.
113. Nikolova D.A., Asangani I.A., Nelson L.D., Hughes D.P., Siwak D.R., Mills G.B., et al. Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. Cancer Res 2009, 69:2461-2470.
114. Rho J.K., Choi Y.J., Lee J.K., Ryoo B.Y., Na I.I., Yang S.H., et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 2009, 63:219-226.
115. Basu D, Nguyen TT, Montone KT, Zhang G, Wang LP, Diehl JA, et al. Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity. Oncogene 2010; ahead of print. doi:10.1038/onc.2010.170.
116. Black P.C., Brown G.A., Inamoto T., Shrader M., Arora A., Siefker-Radtke A.O., et al. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008, 14:1478-1486.
117. Witta S.E., Dziadziuszko R., Yoshida K., Hedman K., Varella-Garcia M., Bunn P.A., et al. ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). Ann Oncol 2009, 20:689-695.
118. Miyanaga A., Gemma A., Ando M., Kosaihira S., Noro R., Minegishi Y., et al. E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib. Oncol Rep 2008, 19:377-383.
119. Engelman J.A., Cantley L.C. The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2006, 12:4372s-4376s.
120. Rogers S.J., Box C., Chambers P., Barbachano Y., Nutting C.M., Rhys-Evans P., et al. Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. J Pathol 2009, 218:122-130.
121. Barr S., Thomson S., Buck E., Russo S., Petti F., Sujka-Kwok I., et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis 2008, 25:685-693.
122. Camirand A., Zakikhani M., Young F., Pollak M. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 2005, 7:R570-R579.
123. Guix M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008, 118:2609-2619.
124. Tennenbaum T., Weiner A.K., Belanger A.J., Glick A.B., Hennings H., Yuspa S.H. The suprabasal expression of alpha 6 beta 4 integrin is associated with a high risk for malignant progression in mouse skin carcinogenesis. Cancer Res 1993, 53:4803-4810.
125. Owens D.M., Romero M.R., Gardner C., Watt F.M. Suprabasal alpha6beta4 integrin expression in epidermis results in enhanced tumourigenesis and disruption of TGFbeta signalling. J Cell Sci 2003, 116:3783-3791.
126. Agelaki S., Spiliotaki M., Markomanolaki H., Kallergi G., Mavroudis D., Georgoulias V., et al. Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Cancer Biol Ther 2009, 8:1470-1477.
127. Fuchs B.C., Fujii T., Dorfman J.D., Goodwin J.M., Zhu A.X., Lanuti M., et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 2008, 68:2391-2399.
128. Lorch J.H., Klessner J., Park J.K., Getsios S., Wu Y.L., Stack M.S., et al. Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J Biol Chem 2004, 279:37191-37200.
129. Carter A. Integrins as target: first phase III trial launches, but questions remain. J Natl Cancer Inst 2010; 102:675-7.
130. Oliveira-Ferrer L., Hauschild J., Fiedler W., Bokemeyer C., Nippgen J., Celik I., et al. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 2008, 27:86.
131. Damiano J.S. Integrins as novel drug targets for overcoming innate drug resistance. Curr Cancer Drug Targets 2002, 2:37-43.
132. Schultze A, Fiedler W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin Invest Drugs 2010; 19:777-88.
133. Gabarra-Niecko V., Schaller M.D., Dunty J.M. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 2003, 22:359-374.
134. Hiscox S, Barnfather P, Hayes E, Bramble P, Christensen J, Nicholson RI, et al. Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells. Breast Cancer Res Treat 2010; ahead of print. doi:1007/s10549-010-0857-4.
135. Ko BS, Chang TC, Chen CH, Liu CC, Kuo CC, Hsu C, et al. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Life Sci 2010; 86:199-206.
136. Li S., Hua Z.C. FAK expression regulation and therapeutic potential. Adv Cancer Res 2008, 101:45-61.
137. Reynolds A.R., Hart I.R., Watson A.R., Welti J.C., Silva R.G., Robinson S.D., et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009, 15:392-400.
138. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12:247-56.
139. Kendall S.E., Najbauer J., Johnston H.F., Metz M.Z., Li S., Bowers M., et al. Neural stem cell targeting of glioma is dependent on phosphoinositide 3-kinase signaling. Stem Cells 2008, 26:1575-1586.
140. Rogers S.J., Box C., Harrington K.J., Nutting C., Rhys-Evans P., Eccles S.A. The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. Expert Opin Ther Targets 2005, 9:769-790.
141. Brader S., Eccles S.A. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 2004, 90:2-8.
142. Hodkinson P.S., Mackinnon A.C., Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int J Radiat Biol 2007, 83:733-741.
143. Bender L.M., Nahta R. Her2 cross talk and therapeutic resistance in breast cancer. Front Biosci 2008, 13:3906-3912.
144. Krasny L, Shimony N, Tzukert K, Gorodetsky R, Lecht S, Nettelbeck DM, et al. An in-vitro tumour microenvironment model using adhesion to type I collagen reveals Akt-dependent radiation resistance in renal cancer cells. Nephrol Dial Transplant 2010; 25:373-80.
145. Song G., Cai Q.F., Mao Y.B., Ming Y.L., Bao S.D., Ouyang G.L. Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1alpha expression through the PI3-K/Akt pathway. Cancer Sci 2008, 99:1901-1907.
146. Burroughs K.D., Oh J., Barrett J.C. DiAugustine RP. Phosphatidylinositol 3-kinase and mek1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor-1?. Mol Cancer Res 2003, 1:312-322.
147. Baumann P., Mandl-Weber S., Oduncu F., Schmidmaier R. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 2009, 315:485-497.
148. van Montfort R.L., Workman P. Structure-based design of molecular cancer therapeutics. Trends Biotechnol 2009, 27:315-328.
149. Guillard S., Clarke P.A., Te Poele R., Mohri Z., Bjerke L., Valenti M., et al. Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle 2009, 8:443-453.
150. Raynaud F.I., Eccles S.A., Patel S., Alix S., Box G., Chuckowree I., et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 2009, 8:1725-1738.
151. Eccles S.A., Massey A., Raynaud F.I., Sharp S.Y., Box G., Valenti M., et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008, 68:2850-2860.
152. Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, Jones C, et al. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 2010; 9:1219-33.
153. Powers M.V., Clarke P.A., Workman P. Death by chaperone: HSP90, HSP70 or both?. Cell Cycle 2009, 8:518-526.
154. Sharp S.Y., Boxall K., Rowlands M., Prodromou C., Roe S.M., Maloney A., et al. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res 2007, 67:2206-2216.
155. Workman P., Burrows F., Neckers L., Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007, 1113:202-216.
156. Bao R., Lai C.J., Wang D.G., Qu H., Yin L., Zifcak B., et al. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol Cancer Ther 2009, 8:3296-3306.
157. Kim Y.S., Alarcon S.V., Lee S., Lee M.J., Giaccone G., Neckers L., et al. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 2009, 9:1479-1492.
158. McCarty MF, Barroso-Aranda J, Contreras F. Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapy. Med Hypotheses 2010; 74:789-97.
159. Prodromou C. Strategies for stalling malignancy: targeting cancer's addiction to Hsp90. Curr Top Med Chem 2009, 9:1352-1368.
160. Tsutsumi S., Beebe K., Neckers L. Impact of heat-shock protein 90 on cancer metastasis. Future Oncol 2009, 5:679-688.
161. Usmani S.Z., Bona R., Li Z. 17 AAG for HSP90 inhibition in cancer-from bench to bedside. Curr Mol Med 2009, 9:654-664.